Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rituximab + Immunotherapy in Follicular Lymphoma
NCT03636503 · Dana-Farber Cancer Institute · PHASE1 · terminated · last registry update 2025-02-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFRSF9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-14Results posted on the registry: M.D. Anderson Cancer Center, Avelumab + Ivuxolimab (NCT03217747)
- 2024-11-07Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + CD8-Positive T-Lymphocyte (NCT03318900)
- 2024-07-30Results posted on the registry: Pfizer, Avelumab + Utomilumab (NCT02554812)
- 2024-07-30Also stopped (terminated): Pfizer, Avelumab + Utomilumab (NCT02554812)
- 2024-06-28Results posted on the registry: Kite, A Gilead Company, Cyclophosphamide + Fludarabine (NCT03704298)
- 2024-06-28Also stopped (terminated): Kite, A Gilead Company, Cyclophosphamide + Fludarabine (NCT03704298)
- 2024-04-18Results posted on the registry: Adrienne G. Waks, Vinorelbine + Trastuzumab (NCT03414658)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision